参附注射液联合缬沙坦胶囊治疗慢性心力衰竭的疗效观察

目的观察参附注射液联合缬沙坦胶囊治疗慢性心力衰竭的临床疗效。方法选择慢性心力衰竭患者79例,随机分为两组。治疗组38例,对照组41例。对照组给予低盐饮食、卧床休息、吸氧、强心、利尿、扩血管等常规抗心衰治疗;治疗组在常规治疗基础上加用:参附注射液50mL+5%葡萄糖注射液250mL,静脉滴注,1次/d;缬沙坦胶囊80mg,口服,1次/d。14d为1个疗程。观察两组患者心率(HR)、左心室舒张末期容积(LVEDV)、左心室射血分数(LVEF)、N端B型脑钠肽前体(N-proBNP)及临床症状改善情况。结果治疗后,治疗组HR(86.6±11.2)次/min、LVEDV(49.64±12.12)mL、N-proBNP(321.3±96.1)pg/mL较治疗前HR(125.3±10.3)次/min、LVEDV(58.21±11.63)mL、N-proBNP(1935.6±283.4)pg/mL明显降低,LVEF(51.26±12.33)%较治疗前LVEF(32.20±9.11)%明显增加;治疗后,对照组HR(97.6±12.1)次/min、LVEDV(53.41±10.30)mL、N-proBNP(567.2±112.8)pg/mL较治疗前HR(126.3±11.4)次/min、LVEDV(57.38±12.31)mL、N-proBNP(1856.9±291.2)pg/mL明显降低、LVEF(40.59±12.81)%较治疗前LVEF(33.54±8.68)%明显增加。治疗组、对照组总有效率分别为92.1%、68.3%。提示两组治疗后与治疗前比较,心功能、临床症状均有明显改善(P<0.05)。治疗后,治疗组与对照组比较,治疗组在改善心功能方面优于对照组(P<0.05)。结论参附注射液联合缬沙坦胶囊治疗慢性心力衰竭临床疗效显著,N端B型脑钠肽前体血浆浓度明显下降,心功能及临床症状明显改善,值得临床应用。

Efficacy of Shenfu Injection Combined with Valsartan Capsules Treatment of Chronic Heart Failure

Objective To observe the clinical efficacy of Shenfu injection combined with valsartan capsule in the treatment of chronic heart failure.M ethods 79 cases of patients with chronic heart failure were randomly divided into two groups.Treatment group,38 patients in the control group of 41 patients.The control group was given a low-salt diet,bed rest,oxygen,cardiac,diuretic,vasodilator conventional therapy,treatment group on the basis of conventional therapy plus：Shenfu injection 50ml ＋5% glucose injection 250ml intravenous infusion,1 times /day;Valsartan capsules 80mg,oral,once /day.The 14-day course of treatment.Observed two groups of patients with heart rate（HR）,left ventricular end-diastolic volume（LVEDV）,left ventricular ejection fraction（LVEF）,the precursor of the N-terminal B-type natriuretic peptide（N-proBNP） and clinical symptoms.Results After treatment,the treatment group HR（86.6±11.2） times/min,LVEDV（49.64±12.12） mL,N-proBNP（321.3±96.1） pg/mL before treatment to HR（125.3 ±10.3） beats/min,LVEDV（58.21±11.63） ml,N-proBNP（1935.6 ±283.4） pg/mL significantly decreased,LVEF（51.26±12.33）% compared with pre-treatment LVEF（32.20±9.11）% significantly increased;after treatment,the control group HR（97.6±12.1）beats/min the LVEDV（53.41±10.30）mL,N-proBNP（567.2±112.8） pg/mL compared with before treatment,the HR（126.3±11.4） beats/min,LVEDV（57.38±12.31）mL of N-proBNP（1856.9±291.2） pg/mL was significantly decreased,LVEF（40.59± 12.81）% compared with pre-treatment LVEF（33.54 ± 8.68）% increased significantly.Treatment group and the control group,the total effective rate was 92.1%,68.3%.Prompted two groups after treatment compared with before treatment,cardiac function,clinical symptoms were significantly improved（P〈0.05）.After treatment,the treatment group compared with control group,the treatment group than the control group（P〈0.05） in improving heart function.C onclusion Shenfu injection combined with valsartan capsule in the treatment of chronic heart failure clinical efficacy significantly,the N-terminal B-type brain natriuretic peptide plasma concentrations were significantly decreased cardiac function and clinical symptoms improved significantly,worthy of clinical application.